Journal article
Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction
Journal of lower genital tract disease, Vol.17(4), pp.397-403
10/2013
DOI: 10.1097/LGT.0b013e31827ed372
PMCID: PMC3982183
PMID: 23609590
Abstract
This study aimed to conduct a representative survey of human papillomavirus (HPV) prevalence and its genotype distribution in invasive anal cancer specimens in the United States.
Population-based archival anal cancer specimens were identified from Florida, Kentucky, Louisiana, and Michigan cancer registries and Surveillance, Epidemiology, and End Results (SEER) tissue repositories in Hawaii, Iowa, and Los Angeles. Sections from 1 representative block per case were used for DNA extraction. All extracts were assayed first by linear array and retested with INNO-LiPA if inadequate or HPV negative.
Among 146 unique invasive anal cancer cases, 93 (63.7%) were from women, and 53 (36.3%) were from men. Human papillomavirus (any type) was detected in 133 cases (91.1%) and 129 (88.4%) contained at least 1 high risk-type, most (80.1%) as a single genotype. Human papillomavirus type 16 had the highest prevalence (113 cases, 77.4%); HPV types 6, 11, 18, and 33 were also found multiple times. Among HPV-16-positive cases, 37% were identified as prototype variant Ep, and 63% were nonprototypes: 33% Em, 12% E-G131G, 5% Af1, 4% AA/NA-1, 3% E-C109G, 3% E-G131T, 2% As, and 1% Af2. No significant differences in the distributions of HPV (any), high-risk types, or HPV-16/18 were seen between sex, race, or age group.
The establishment of prevaccine HPV prevalence in the United States is critical to the surveillance of vaccine efficacy. Almost 80% of anal cancers were positive for the vaccine types HPV-16 or HPV-18, and in 70%, these were the only types detected, suggesting that a high proportion might be preventable by current vaccines.
Details
- Title: Subtitle
- Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction
- Creators
- Martin Steinau - Centers for Disease Control and PreventionElizabeth R UngerBrenda Y HernandezMarc T GoodmanGlenn CopelandClaudia HopenhaynWendy CozenMaria S SaberYoujie Huang - Florida Department of HealthEdward S PetersCharles F LynchEdward J WilkinsonMangalathu S RajeevanChristopher LyuMona Saraiya
- Resource Type
- Journal article
- Publication Details
- Journal of lower genital tract disease, Vol.17(4), pp.397-403
- DOI
- 10.1097/LGT.0b013e31827ed372
- PMID
- 23609590
- PMCID
- PMC3982183
- NLM abbreviation
- J Low Genit Tract Dis
- ISSN
- 1526-0976
- eISSN
- 1526-0976
- Publisher
- Ovid Technologies (Wolters Kluwer Health); United States
- Grant note
- U58 DP000844 / NCCDPHP CDC HHS U58 DP000807 / NCCDPHP CDC HHS U58 DP000810 / NCCDPHP CDC HHS 5U58DP000844-5 / NCCDPHP CDC HHS N01-PC-35137 / NCI NIH HHS N01-PC 2010-00035 / NCI NIH HHS N01PC35139 / NCI NIH HHS N01PC35137 / NCI NIH HHS U58 DP000812 / NCCDPHP CDC HHS 1U58DP000807-3 / NCCDPHP CDC HHS 5U58DP000769-5 / NCCDPHP CDC HHS 5U58DP000812-5 / NCCDPHP CDC HHS N01PC35143 / NCI NIH HHS N01-PC-35139 / NCI NIH HHS 5U58DP000810-5 / NCCDPHP CDC HHS U58 DP000769 / NCCDPHP CDC HHS N01-PC-35143 / NCI NIH HHS
- Language
- English
- Date published
- 10/2013
- Academic Unit
- Epidemiology
- Record Identifier
- 9983995159702771
Metrics
14 Record Views